INTRODUCTION
Ataxia-telangiectasia (AT; OMIM 208900) is an autosomal recessive neurodegenerative disease caused by mutations in the ataxia telangiectasia mutated (ATM) gene [1] . The ATM gene codes for ATM kinase, which plays a role in cell cycle control and DNA repair [2] . Over 400 ATM mutations have been described so far [3] . AT is characterized by cerebellar ataxia, oculocutaneous telangiectasia, increased radiosensitivity, growth retardation, predisposition to malignancies and diabetes mellitus type II, and a primary cellular and humoral immunodeficiency causing recurrent sinopulmonary infections [4] . The immunodeficiency is caused by impaired double-strand break repair processes, such as V(D)J recombination [5] and class-switch recombination [6, 7] , and features a reduced number of circulating T-cells (in particular CD3+CD4+CD45RA+ naïve T-cells) and B-cells, frequently causing decreased or absent serum IgA and IgG 2 [8, 9] . An estimated 10% of AT patients have decreased IgA and IgG levels with normal to increased IgM levels [10] , designated as 'hyper IgM phenotype with hypogammaglobulinemia' (AT-HIGM). AT is incurable and patients have a reduced life expectancy due to cancer, pulmonary disease, and infections [11] .
The clinical spectrum of AT is variable [12] with residual kinase activity and the related type of ATM mutation contributing to the life expectancy [11, 13] . Variant AT patients have a milder clinical phenotype and a longer lifespan compared to classical AT patients [11] [12] [13] ; their longer life expectancy may be attributed to less severe immunodeficiency [8, 9] and delayed onset of cancer [11] .
Much is known about the pathogenesis of AT but knowledge of factors predicting survival is lacking. To further individualize follow-up programs for AT patients, and eventually select eligible patients for future therapeutic trials, better knowledge on factors that contribute to survival is needed.
The aim of this study was to identify such factors in both classical and variant AT. 
Ascertainment of study cohort
Data were retrospectively collected from Dutch and Icelandic cohorts of AT patients. For patients previously described by Verhagen et al. [13] , the follow-up period was extended by six years. The clinical diagnosis of AT was confirmed by the identification of pathogenic ATM mutations in all subjects. The ATM mutation analysis and the measurements of ATM protein and ATM kinase activity in patients with available lymphoblast cell lines were performed using previously described methods [14, 15] . Data on age, gender, nationality, age and cause of death, immunoglobulin levels of IgA, IgG, IgG 2 , IgM, and lymphocyte subsets (all pre-treatment, in case of immunoglobulin replacement therapy), and presence of cancer were collected from the cohort database or the medical records of the patient's primary hospital. Immunoglobulin plasma levels and lymphocyte subsets were assessed using methods previously described [16] , and compared to age-related reference values [17, 18] . The follow-up period was defined as starting at birth and continuing until death or August 31, 2014, whichever came first. Patients lost to follow-up were excluded from the study. This study was approved by the Regional Committee on Research involving Human Subjects Arnhem-Nijmegen.
Patient definitions
The patients were classified into four groups, based on the presence of ATM protein and ATM kinase activity. The classical AT patients comprised patients without detectable ATM protein (group 1), patients with ATM protein but without ATM kinase activity (group 2), and patients with missing data on ATM protein and ATM kinase activity, but with clinical phenotypes similar to those in groups 1 and 2 (Supplement 1) (group 3). Group 4 consisted of variant AT patients with residual kinase activity.
Patients with decreased IgG and IgA levels but with normal or elevated IgM levels at the time of diagnosis were classified as AT-HIGM (group 1a), and those with normal total IgG levels as group 1b.
Literature search
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To supplement the data from our cohort, we searched all available literature for reports on patients with AT-HIGM. We searched all available literature until January 2016 through the electronic databases PubMed, EMBASE, the Cochrane Library, and Web of Science. For all patients that were alive at time of publication, the first authors of the papers were contacted for additional information on survival.
Statistical analysis
Using 
RESULTS
Cohort description
The total cohort consisted of 63 patients. Two patients that were lost to follow-up were excluded from the analysis, leading to inclusion of 61 AT patients ( Figure 1a ). In total, 50 of these patients were previously described by our research group [13] in a genotype-phenotype correlation study, while 27 patients were also described in other reports [8, [19] [20] [21] [22] [23] . Variant (13) Classical (48) Patients (61) ATM + (19) No ATM (17) HIGM (7) No HIGM (10) No data on ATM (12) 
Alive (29) Patients (61) < 30 yrs (16) > 30 yrs (13) > 30 yrs (5) < 30 yrs (27) Classical (4) Variant (9) Classical (16) Variant (0) Classical (2) Variant (3) Classical (26) Variant (1) A
Survival analyses
As shown in Figure 2 , patients with classical AT generally died at a much younger age than variant AT patients. The corresponding hazard ratio for classical AT compared to variant AT was 5.9 (95% CI 2.0-17.7). Only very slight differences in HR were observed when gender was included as co-variable and after exclusion of AT-HIGM patients or patients with less than 10 years of follow-up (Supplement 3 
Malignancy
Among the classical AT patients, 21 
Immunology
IgG 2 deficiency
AT patients with an IgG 2 deficiency had greatly reduced survival compared to patients with normal 
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Hyper IgM phenotype
The survival of AT patients with AT-HIGM (group 1a) was much worse than that of classical AT patients without ATM protein but with normal IgG levels (group 1b)(HR 8.0, 95%CI 1.6-40.1) ( Figure   5 ) or other AT patients with normal IgG levels (Supplement 3). All patients with AT-HIGM died before the age of 15, three from a malignancy (two of which were lymphomas), and four from respiratory failure. In group 1b, five patients died from a malignancy (50%) and one from an unknown cause (Table 1 ).
In addition to the seven patients in our cohort, 15 other patients with AT-HIGM were described in the literature [20, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . We received additional information on survival for five patients that were alive at the time of publication (patients L2a, L3, L6, L7, and L14, Table 2 ). Eight of these 15 patients were reported to have died: seven between 2 and 12 years of age and one at age 24. The remaining patients (n=7) were alive at the time of publication, but at least three of them died after publication, at 10, 11, and 15 years of age. 
DISCUSSION
This cohort study confirmed that 
Variant AT and malignancies
Some have suggested that the survival time of AT patients has not changed in the last 50 years [11] .
However, classical AT patients surviving more than 30 years were rarely described in the past,
whereas six patients in the present study reached this age. It is well-known that patients with classical AT have a shorter life expectancy of approximately 20 years [13, 34] , mainly due to earlier onset of malignancies [35, 36] , compared to variant AT patients. The results from the present study are in accordance with this literature, with a difference of 27 years in median age at diagnosis of malignancies. Classical AT patients without malignancies had a 2.5 times higher overall chance of survival compared to classical patients with a malignancy and their main cause of death was respiratory insufficiency, which is also in line with the available literature [11, 34] . We believe that respiratory diseases may contribute to severe complications of cancer treatment and a short survival time after cancer diagnosis in AT patients with malignancies.
The 81% mortality rate due to malignancies among classical AT patients and the death of four out of five variant AT patients with a malignancy are in accordance with the data of Micol et al., who described a mortality rate of 90% for hematological malignancies and 83.3% for carcinomas [11] . The median time of survival after diagnosis was less than one year for classical patients in both our and their cohort [11] . In our variant AT patients, the youngest age at diagnosis of cancer was 23 years.
This late occurrence of malignancies is probably due to the residual kinase activity and normal immunoglobulin levels protecting these patients from the development of lymphoid malignancies, especially in childhood [35, 36] . All patients without a malignancy in the variant group were still alive at the end of follow-up. Future studies need longer follow-up times to determine the final course of disease in variant AT patients.
Immunology
Immunodeficiency in general has been associated with an increased risk of cancer [35] . This study shows that malignancies were not more frequent in AT patients with IgA deficiency compared to those with normal IgA levels. In contrast, malignancies were more common and the major cause of death in IgG 2 deficient patients compared to patients with normal IgG 2 levels. Respiratory failure was not the major cause of death in this group, although low IgG 2 levels have been associated with a decreased polysaccharide antibody response, possibly causing increased susceptibility to respiratory tract infections [37] . This may be explained by the successful administration of antibiotic prophylaxis and immunoglobulin replacement therapy to these patients.
The majority of classical AT patients had reduced levels of IgA but none of the variant AT patients were IgA deficient, which corresponds with the results of Staples et al. [9] . Based on similar percentages of patients with IgG 2 or IgA deficiency in group 1b compared to group 2 and the variability in immunoglobulin levels between siblings (for example IgG 2 levels in families 9 and 24 and 45 and IgA levels in families 18, 20 and 24), it seems that the immune defects in AT do not correlate with detectability of the ATM protein.
The AT-HIGM phenotype is caused by class-switch recombination deficiency and is characterized by decreased levels of serum IgG (and IgG subclasses) and IgA, with normal or increased levels of serum IgM [38] . Since recurrent sinopulmonary infections in patients with AT-HIGM manifest at a very young age, often before ataxia and telangiectasia are present or recognized, patients with HIGM are at risk of being misdiagnosed with 'HIGM of undetermined cause' instead of AT-HIGM [8, 20, [24] [25] [26] .
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The present study, as well as all available data from the literature, clearly revealed that HIGM strongly reduces the life expectancy in AT patients, with respiratory failure being a common cause of death. All seven patients in our cohort, and at least 10 out of 15 patients that were described earlier, died before the age of 15. Of all 22 patients with AT and HIGM described so far, no more than 5
(23%) survived beyond adolescence. Despite intravenous immunoglobulin substitution therapy, the AT-HIGM patients in the present cohort developed respiratory insufficiency before the age of 15. This is a major point of interest since lung function is normal in most adolescents with AT [39] . In our cohort, patients with the same ATM mutations expressed different phenotypes for AT-HIGM, even some that were siblings. This has also been described previously [25, 27, 30] (Table 2) and confirms that no correlation exists between ATM mutations and AT-HIGM phenotypes.
As AT is a severe disease, affecting -among others -the nervous system and the immune system, high-risk therapies targeting the underlying molecular aspects may be considered. This is illustrated by former administration of stem cell transplantation to patients with AT [31, 40, 41] and in patients with other neurodegenerative diseases [42] and primary immunodeficiencies [43] . Due to the poor prognosis of AT patients with HIGM, we believe that these patients are among the first eligible candidates to study the efficacy and safety of such therapies, as this group is expected to profit most from this therapy. Needless to say, no other accountable cause for the IgG deficiency should exist, and HIGM should be present since early childhood and not be a paraneoplastic feature. Since neonatal screening for severe primary immunodeficiency diseases is upcoming in some countries, patients may be diagnosed with AT before the first clinical symptoms emerge [44, 45] . The presence of HIGM in some of these young pre-symptomatic children can be used as a prognostic marker for a poor outcome.
Strengths and limitations
The strengths of this study are the large number of well-characterized AT patients, the inclusion of patients from different ethnicities, and the extensiveness of the data set. All but the Icelandic patients lived in the Netherlands and benefited from the National Health Care system.
The present cohort contained many young children, but sensitivity analyses excluding patients with <10 years of follow-up did not lead to essential changes in results. As groups 1a and 4 included mainly female patients, adjustments for gender did affect some estimates, but not the interpretation of the results. While studying the Kaplan-Meier curves, for instance in Figure 2 , one may erroneously assume that over 50% of variant AT patients survived beyond 50 years of age, and that 25% of classical AT patients survived beyond 40 years of age. As listed in Table 1 and in the table underneath Given the rarity of AT, this study includes a relatively large number of patients. Nevertheless, the main limitations of the study are due to small sample sizes, especially in subgroup analyses. As a result, the data must be interpreted with caution and further investigations with larger cohorts of AT patients are needed to confirm our results. Fortunately, an international effort to register as many patients as possible is now ongoing. Exclusion of patients that were lost to follow-up, missing patients with a mild phenotype that were not diagnosed, publication bias, and unavailability of immunoglobulin levels may have caused selection and/or information bias, but the number of patients with missing data was small. Although this study spanned several decades and management of AT patients might have changed over the years, survival was not influenced by cohort effects of year of birth or diagnosis.
CONCLUSION
AT is known as a disease with a highly reduced life expectancy, but we described several patients with classical AT who survived longer than would be expected. On the other hand, this study is the first to show that IgG 2 deficiency and HIGM negatively influence survival in AT patients, and to give an overview of all patients with AT and HIGM described in the literature. We believe that AT patients with HIGM are at extremely high risk of early death, and are therefore most eligible for future therapeutic trials. 
